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SNM - indications
•Urological
• Refractory OAB – 75%
• Wet -1997
• Dry -1999
• No obstructive urinary retention –NOUR -1999 – 25%
•Proctological
• Fecal incontinence -2011
• Chronic constipation -Europe
OAB treatment
• First-line treatment
• Behavioural therapies -bladder training (BT) and pelvic floor muscle therapy (PFMT) 
• Lifestyle changes -fluid and caffeine intake, diet, weight loss, management of bowel regularity, and
optimization of other comorbidities







• Which is the preferred/first, third line option remains open to debate
• Failed BTXA therapy
• due to either lack of efficacy, urinary retention, or adverse reaction
• patients may be candidates for SNM.
SNM - safety
• The most common adverse event
• pain at the implant site
in most studies varies between 3% and 42%
• Other adverse events reported
• lead migration (1–21%)
• bowel dysfunction (4–7%)
• infection(4–10%).
Banakhar MA, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder:
an emerging tool for an old problem. Ther Adv Urol. 2012;4:179–185.
SNM - efficacy
• Success rates, have been reported between 64% and 88%.
Banakhar MA, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder:
an emerging tool for an old problem. Ther Adv Urol. 2012;4:179–185.
SNM after BTXA
• To date, there has been little data on the efficacy of SNM after BTXA.
• Smits et al reported
• 70% success rate for first-stage SNM (n=20).
• 79% success at 1 year with the Permanent implantable pulse generator (IPG) 
(n=14) 
Smits MAC, Oerlemans D, Marcelissen TAT, Kerrebroeck PEV Van, De Wachter SGG. Voiding Dysfunction Sacral 
Neuromodulation in Patients with Idiopathic Overactive Bladder after Initial Botulinum Toxin Therapy. J Urol. 
2013;190:2148-2152. doi:10.1016/j.juro.2013.07.017.
• Success rate of 70 % in BTXA-naïve patients (n=47)
• 63.9 % for prior BTXA (n=36). P=0,5
• 64.0 % for prior “ineffective” BTXA (n=25) P=0,6
• First-stage SNM success rate
• 68 % (n=19) ≤ 2 BTXA treatments,
• 58 % (n=17) ≥ 3 BTXA treatments (P=0.5).
Hoag N, Plagakis S, Pillay S, Edwards AW, Gani J. Sacral neuromodulation for refractory overactive bladder after prior 
intravesical onabotulinumtoxinA treatment. Neurourol Urodyn. 2017. doi:10.1002/nau.23117.
SNM after BTXA
• SNM as the first therapeutic option for refractory idiopathic OAB-wet
• is cost effective after 3 years
• €21,259/QALY), (ICUR < 40.000 €/QALY) 
• and becomes dominant at 10 years
• less costly— €333.22 saved
• more effective— 0.59 QALY gained
Bertapelle MP, Vottero M, Popolo G Del, et al. Sacral neuromodulation and Botulinum toxin A for refractory 
idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 
2015. doi:10.1007/s00345-014-1401-7.
SNM - cost-effectiveness related to BTXA
Bertapelle MP, Vottero M, Popolo G Del, et al. Sacral 
neuromodulation and Botulinum toxin A for refractory 
idiopathic overactive bladder: a cost-utility analysis in 
the perspective of Italian Healthcare System. World J 
Urol. 2015. doi:10.1007/s00345-014-1401-7.
SNM - cost-effectiveness
cost effective (ICUR < 40.000 €/QALY
SNM - cost-effectiveness
In Europe, the relative cost-effectiveness of SNM and BTXA has been
investigated in Spain (1), Holland (2) and UK (3)
1. Arlandis S, Castro D, Errando C et al (2011) Cost-effectiveness of sacral neuromodulation compared to 
Botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Health
14:219–2287.
2. Leong RK, de Wachter SG, Joore MA et al (2011) Cost-effectiveness analysis of sacral neuromodulation and 
Botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 108:558–5648. 
3. Walleser S, Betts C, Hallas N et al (2012) Sacral nerve modulation (SNM) for the treatment of idiopathic
refractory overactive bladder: cost-effective in the UK compared to optimal medical therapy, Botulinum toxin A 
(BoNT-A) and percutaneous tibial nerve stimulation (PTNS). Value Health 15:A354–A3559.
as well as in the USA (4) and Canada (5)
• all of them suggesting that
4. Ganz M, Clemens JQ, Anger J et al (2011) A Markov model comparing sacral neuromodulation
and Botulinum toxin-A for medicare patients with idiopathic overactive bladder refractory to 
conservative care. Value Health 14:A211–A214
5. Hassouna M, Corcos J, Dwyer N et al (2012) Cost-effectiveness of sacral neuromodulation in 
refractory overactive bladder: a Canadian perspective. J Urol 187(4S):e117
SNM is cost-effective in the medium and long-term
SNM - cost-effectiveness
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Neurourology and Urodynamics 2017 DOI 10.1002/nau
Noblett et al.
Non-rechargeable - Interstim II
• Current SNM device are not rechargeable, and require neurostimulator
replacement every 3–6 years.
• Long term success rate proven to 5 years
• Acceptable cost-effectiveness profile
• Substantial upfront costs
• Replacement expenditures are the major cost contributor
An increased battery life is a desirable feature not only for patients, but also for
healthcare payers.
Rechargeable neurostimulation systems are currently being developed and tested
Rechargeable devices
Cost profiles
• Analyze and compare the cost profiles of rechargeable versus non-rechargeable SNM devices
• Estimate the resulting long-term budget impact to payers
• Based on hypothetical scenarios
• Rechargeable strategy
• reported lifetime of rechargeable spinal cord stimulation (SCS) systems (Eon MiniTM Rechargeable IPG; 
Nevro Senza SCS System)
• Non-rechargeable strategy






• Rechargeable SNM systems are not yet commercially available
• Long-term performance is based on the best available evidence from comparable 
rechargeable systems used in the field of SCS.




• The device was approved in 2016 for the treatment of OAB in Europe and Canada
• Consists of a small volume rechargeable neurostimulator (60% smaller than Interstim)
• Approved for head MRI like Interstim.
• The battery is rechargeable with a 15-year lifetime in the body
• There is no real-life data to support the efficacy up to 15 years
• Recharging, performed via a wireless charger, secured to the patient either by disposable carrier or
a flexible belt, would be expected to take between 1 and 2 hours
Guzman-Negron JM, Goldman HB. New Devices and Technologies for the 
Management of Overactive Bladder. doi:10.1007/s11934-017-0739-y.
Axonics
• There is currently a prospective multicenter clinical study (RELAX-OAB trial) designed to confirm
the performance of the Axonics SNM System
Nuvectra
• Nuvectra Corporation submitted in 2/2017 to the FDA and CE Marking authorities for Virtis™ 
approval
• Is full body MRI compatible. 
• Is dual channel, therefore can perform bilateral stimulation.
• Can last up to 10 years. 
Pros and cons
• Rechargeable is not suitable for everyone
• InterStim can fit patients' lifestyles, providing FREEDOM to live without thinking
about their therapy. 
• At this time, there are no published data to the Axonics system.
Pros and cons
• Coupling with patient programmer or recharger might be more difficult with a 
smaller device
• The position, changes in depths and the orientation of the device may vary with time
• As a result, the efficiency of the recharge may decreased and more heat may be
generated over time
Plourde B, Vallez L, Nelson-Cheeseman B, Abraham J. Transcutaneous Recharge: A Comparison of 
Numerical Simulation to In Vivo Experiments. Neuromodulation. 2017. doi:10.1111/ner.12627.
Pros and cons
• Numerical simulation to predict tissue temperatures in changes in depths and orientation
• The results show that temperatures do not rise to a level which can cause thermal injury.
• That level is generally considered to be 43°C.
Abraham JP, Plourde BD. Validation of Numerically Simulated Tissue Temperatures during 
Transcutaneous Recharge of Neurostimulation Systems. Neuromodulation. 2016. doi:10.1111/ner.12331.
Superficial Deep
Conclusions
•Today SNM is Interstim II
• Safe
• Long term success rate proven to 5 years, even in failed-BTXA
• Cost-effective in the medium and long-term
• Rechargeable SNM
• Not suitable for everyone
• Probably in the next 2 years – Axonics, Interstim recarregável
• May deliver significant cost savings
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